Belbuca
Small molecule
Evidence outlook
Approved: Chronic Pain
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01633944 NCT01633944 · Chronic Pain Registry: NCT01633944 | 3 | Change From Baseline to Week 12 in Average Daily Pain Intensity Scores (Baseline, Week 12) 2013-12 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
View 1 more trial
NCT01675167 NCT01675167 · Chronic Pain Registry: NCT01675167 | 3 | Change From Baseline to Week 12 in Average Daily Pain Intensity Scores (Baseline, week 12) 2014-06 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
This drug's own stage for Chronic Pain: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Belbuca: this drug | Approved | Small molecule | Opioid receptors (mu-opioid receptor partial agonist, kappa-opioid receptor antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Oxycodone (Xtampza ER) | Approved | Small molecule | Opioid receptors (mu-opioid receptor) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Belbuca to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2031 (1)
October 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent